Royal Biologics gets FDA clearance for wound matrix

Royal Biologics has received FDA clearance for its Fibrinet® PRF Wound Matrix, a product designed for managing cutaneous wounds. This approval marks a significant milestone for the company in the regenerative medicine and advanced wound care sector. The Fibrinet matrix is expected to offer improved treatment options for patients suffering from chronic or difficult-to-heal wounds, underscoring advancements in medical technology.